{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:32:47Z","timestamp":1792132367363,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medj.2026.101151","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:51:11Z","timestamp":1780584671000},"page":"101151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene therapy and cost-effectiveness analysis: Current issues and future research"],"prefix":"10.1016","volume":"7","author":[{"given":"Scott","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marric","family":"Buessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abena","family":"Otu-Adum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6777","authenticated-orcid":false,"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101151_bib1","unstructured":"Centers for Medicare and Medicaid Services (2025). NHE Fact Sheet. https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/national-health-expenditure-data\/nhe-fact-sheet."},{"key":"10.1016\/j.medj.2026.101151_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023\u2014an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J. Gene Med."},{"key":"10.1016\/j.medj.2026.101151_bib3","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.medj.2026.101151_bib4","article-title":"Balancing the use of cost-effectiveness analysis across all types of health care innovations","author":"Baumgardner","year":"2017","journal-title":"Health Affairs Forefront"},{"key":"10.1016\/j.medj.2026.101151_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2023.03.1480","article-title":"HTA51 Impact of ICER Assessments on Payer Decision Making in the United States","volume":"26","author":"Zheng","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib6","series-title":"Estimating the Financial Impact of Gene Therapy in the US","author":"Wong","year":"2021"},{"key":"10.1016\/j.medj.2026.101151_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41434-023-00419-9","article-title":"The estimated annual financial impact of gene therapy in the United States","volume":"30","author":"Wong","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.medj.2026.101151_bib8","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"key":"10.1016\/j.medj.2026.101151_bib9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating Cost-Effectiveness \u2014 The Curious Resilience of the $50,000-per-QALY Threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101151_bib10","article-title":"Value frameworks for rare diseases: should they be different?","author":"Jena","year":"2017","journal-title":"Health Affairs Forefront"},{"key":"10.1016\/j.medj.2026.101151_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the orphan drug act?","volume":"14","author":"Herder","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.medj.2026.101151_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104698","article-title":"Estimating the number of diseases\u2013the concept of rare, ultra-rare, and hyper-rare","volume":"25","author":"Smith","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.medj.2026.101151_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1750-1172-7-74","article-title":"Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?","volume":"7","author":"Hughes-Wilson","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib14","doi-asserted-by":"crossref","DOI":"10.3402\/jmahp.v4.33039","article-title":"Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement","volume":"4","author":"Schlander","year":"2016","journal-title":"J. Mark. Access Health Policy"},{"key":"10.1016\/j.medj.2026.101151_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1750-1172-8-198","article-title":"Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries","volume":"8","author":"Morel","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-015-0305-y","article-title":"The quality of economic evaluations of ultra-orphan drugs in Europe\u2013a systematic review","volume":"10","author":"Schuller","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","article-title":"Economic modeling considerations for rare diseases","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-015-0269-y","article-title":"Principles for consistent value assessment and sustainable funding of orphan drugs in Europe","volume":"10","author":"Gutierrez","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","article-title":"Assessing the economic challenges posed by orphan drugs","volume":"23","author":"Drummond","year":"2007","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.medj.2026.101151_bib20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jval.2018.12.013","article-title":"Important considerations in modeling the cost-effectiveness for the first Food and Drug Administration\u2013approved gene therapy and implications for future one-time therapies","volume":"22","author":"Buessing","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib21","unstructured":"Office, G.A. (2021). Rare Diseases: Although Limited, Available Evidence Suggests Medical and Other Costs Can be Substantial. October 18, 2021, GAO-22-104235. https:\/\/www.gao.gov\/products\/gao-22-104235."},{"key":"10.1016\/j.medj.2026.101151_bib22","article-title":"Voretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease: Effectiveness and Value; Final Evidence Report.","author":"Banken","year":"2019"},{"key":"10.1016\/j.medj.2026.101151_bib23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1464-5491.2008.02430.x","article-title":"Health utility values associated with diabetic retinopathy","volume":"25","author":"Lloyd","year":"2008","journal-title":"Diabet. Med."},{"key":"10.1016\/j.medj.2026.101151_bib24","unstructured":"Tice JA, W.S., Herce-Hagiwara B, Fahim SM, Moradi A, Sarker J, Chu J, Agboola F, and Pearson SD, R.D. (2022). Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A: Effectiveness and Value; Evidence Report. Institute for Clinical and Economic Review. December 22, 2022. https:\/\/icer.org\/assessment\/hemophilia-a-and-b-2022\/."},{"key":"10.1016\/j.medj.2026.101151_bib25","unstructured":"National Institute for Health and Care Excellence (2025). Exagamglogene autotemcel for treating sickle cell disease [ID4016]. National Institute of Health and Care Excellence. February 26, 2025. https:\/\/www.nice.org.uk\/guidance\/ta1044\/evidence\/final-draft-guidance-committee-papers-pdf-15249475982."},{"key":"10.1016\/j.medj.2026.101151_bib26","unstructured":"Beaudoin F, T.P., Nikitin D, Campbell J, Spackman E, McKenna A, and Pearson SD, R.D. (2023). Gene Therapies for Sickle Cell Disease: Effectiveness and Value; Evidence Report. Institute for Clinical and Economic Review. August 21, 2023. https:\/\/icer.org\/assessment\/sickle-cell-disease-2023\/."},{"key":"10.1016\/j.medj.2026.101151_bib27","unstructured":"Satija, B. (2023). Vertex\/CRISPR price sickle cell disease gene therapy at $2.2 mln. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/vertexcrispr-price-sickle-cell-disease-gene-therapy-22-mln-2023-12-08\/."},{"key":"10.1016\/j.medj.2026.101151_bib28","series-title":"Pharmaceutical Pricing and R&D as a Global Public Good","author":"Frech","year":"2023"},{"key":"10.1016\/j.medj.2026.101151_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib30","unstructured":"National Bleeding Disorders Foundation (2025). Pfizer Discontinues Beqvez Hemophilia B Gene Therapy. https:\/\/www.bleeding.org\/news\/pfizer-discontinues-beqvez-hemophilia-b-gene-therapy."},{"key":"10.1016\/j.medj.2026.101151_bib31","unstructured":"Santhosh, C. (2025). Pfizer stops commericalization of hemophilia gene therapy Beqvez. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/pfizer-says-it-will-end-global-development-gene-therapy-beqvez-nikkei-reports-2025-02-20\/."},{"key":"10.1016\/j.medj.2026.101151_bib32","unstructured":"Daniel, G.W., Greene, K., Lopez, M.H., Schneider, M., Rotter, J., McClellan, M.B., Silcox, C., Qian, J., Fiore, N., and Higgins, A. (2019). Breakthroughs and Barriers: Advancing Value-Based Payment for Transformative Therapies. Duke-Margolis Center for Health Policy. May 1, 2019. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2021-05\/advancing_vbp_for_transformative_therapies.pdf."},{"key":"10.1016\/j.medj.2026.101151_bib33","series-title":"AveXis Announces Innovative Zolgensma\u00ae Gene Therapy Access Programs for US Payers and Families","year":"2019"},{"key":"10.1016\/j.medj.2026.101151_bib34","series-title":"At over $2 Million Zolgensma Is the World's Most Expensive Therapy","author":"Cohen","year":"2019"},{"key":"10.1016\/j.medj.2026.101151_bib35","unstructured":"Wilkerson, J. (2019). Zolgensma's Pay Model Avoids Medicaid Best Price Pitfall. https:\/\/insidehealthpolicy.com\/inside-drug-pricing-daily-news\/zolgensma%E2%80%99s-pay-model-avoids-medicaid-best-price-pitfall."},{"key":"10.1016\/j.medj.2026.101151_bib64","unstructured":"Food and Drug Administration (2025). Approved Cellular and Gene Therapy Products. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"10.1016\/j.medj.2026.101151_bib36","unstructured":"National Cancer Institute Cancer Stat Facts: Bladder Cancer. National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"10.1016\/j.medj.2026.101151_bib37","series-title":"Growth in U.S. Population Shows Early Indication of Recovery amid COVID-19 Pandemic","year":"2022"},{"key":"10.1016\/j.medj.2026.101151_bib38","series-title":"IBM Micromedex\u00ae Red Book\u00ae","year":"2025"},{"key":"10.1016\/j.medj.2026.101151_bib39","unstructured":"Ferring Pharmaceuticals (2024). Prescribing Information: ADSTILADRIN."},{"key":"10.1016\/j.medj.2026.101151_bib40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13998","article-title":"Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres","volume":"26","author":"Soucie","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.medj.2026.101151_bib41","unstructured":"Pfizer (2024). Prescribing Information: BEQVEZ."},{"key":"10.1016\/j.medj.2026.101151_bib42","unstructured":"Centers for Disease Control and Prevention. Data and Statistics on Sickle Cell Disease. https:\/\/www.cdc.gov\/sickle-cell\/data\/index.html."},{"key":"10.1016\/j.medj.2026.101151_bib43","unstructured":"Vertex Pharmaceuticals (2024). Prescribing Information: CASGEVY."},{"key":"10.1016\/j.medj.2026.101151_bib44","unstructured":"Venugopal, V., and Pavlakis, S. (2023). Duchenne Muscular Dystrophy. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482346\/."},{"key":"10.1016\/j.medj.2026.101151_bib45","unstructured":"Sarepta Therapeutics, I., , (2024). Prescribing Information: ELEVIDYS."},{"key":"10.1016\/j.medj.2026.101151_bib46","unstructured":"CSL Behring (2022). Prescribing Information: HEMGENIX."},{"key":"10.1016\/j.medj.2026.101151_bib47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-022-02274-0","article-title":"Symptoms and impacts of aromatic l-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function","volume":"17","author":"Williams","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib48","unstructured":"PTC Therapeutics (2024). Prescribing Information: KEBILIDI."},{"key":"10.1016\/j.medj.2026.101151_bib49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcyt.2024.03.487","article-title":"Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States","volume":"26","author":"Adang","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.medj.2026.101151_bib50","unstructured":"Orchard Therapeutics (2024). Prescribing Information: LENMELDY."},{"key":"10.1016\/j.medj.2026.101151_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/APO.0000000000000290","article-title":"Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations","volume":"9","author":"Talib","year":"2020","journal-title":"Asia. Pac. J. Ophthalmol."},{"key":"10.1016\/j.medj.2026.101151_bib52","unstructured":"Spark Therapeutics, I., , (2022). Prescribing Information: LUXTURNA."},{"key":"10.1016\/j.medj.2026.101151_bib53","unstructured":"bluebird bio (2023). Prescribing Information: LYFGENIA."},{"key":"10.1016\/j.medj.2026.101151_bib54","series-title":"$2.9 Million Gene Therapy for Severe Hemophilia Is Approved by FDA","author":"Perrone","year":"2023"},{"key":"10.1016\/j.medj.2026.101151_bib55","unstructured":"BioMarin Pharmaceutical Inc. (2023). Prescribing Information: ROCTAVIAN."},{"key":"10.1016\/j.medj.2026.101151_bib56","unstructured":"Alsaleem, M.H., N; Saadeh, L. (2024). Adrenoleukodystrophy. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562328\/."},{"key":"10.1016\/j.medj.2026.101151_bib57","unstructured":"bluebird bio (2024). Prescribing Information: SKYSONA."},{"key":"10.1016\/j.medj.2026.101151_bib58","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","article-title":"Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry","volume":"152","author":"Fine","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.medj.2026.101151_bib59","unstructured":"Krystal Biotech, I., , (2023). Prescribing Information: VYJUVEK."},{"key":"10.1016\/j.medj.2026.101151_bib60","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","article-title":"Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US","volume":"178","author":"Belter","year":"2024","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.medj.2026.101151_bib61","unstructured":"Novartis (2025). Prescribing Information: ZOLGENSMA."},{"key":"10.1016\/j.medj.2026.101151_bib62","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2024-200292","article-title":"Estimated Prevalence of \u03b2-Thalassemia in the United States in 2023","volume":"144","author":"Fu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101151_bib63","unstructured":"bluebird bio (2022). Prescribing Information: ZYNTEGLO."},{"key":"10.1016\/j.medj.2026.101151_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"Ades","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.medj.2026.101151_bib66","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jval.2018.01.019","article-title":"Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses","volume":"21","author":"Soares","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib67","first-page":"793","article-title":"Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold","volume":"25","author":"Garrison","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.medj.2026.101151_bib68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s13023-024-03382-9","article-title":"Uncertainties in evaluating the health-related quality of life and disease burden of people with rare diseases and their caregivers in NICE HST submissions","volume":"19","author":"Looby","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib69","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","article-title":"A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries","volume":"7","author":"Czech","year":"2019","journal-title":"Front. Public Health"},{"key":"10.1016\/j.medj.2026.101151_bib70","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","article-title":"The History and Future of the ISPOR Value Flower: Addressing Limitations of Conventional Cost-Effectiveness Analysis","volume":"25","author":"Neumann","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2217\/rme-2020-0169","article-title":"The Use of Innovative Payment Mechanisms for Gene Therapies in Europe and the USA","volume":"16","author":"J\u00f8rgensen","year":"2021","journal-title":"Regen. Med."},{"key":"10.1016\/j.medj.2026.101151_bib72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13023-024-03249-z","article-title":"Challenges for gene therapy in the financial sustainability of health systems: a scoping review","volume":"19","author":"Ossandon","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.medj.2026.101151_bib73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40273-023-01335-x","article-title":"Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid","volume":"42","author":"Zemplenyi","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.medj.2026.101151_bib74","unstructured":"Centers for Medicare and Medicaid Services (2025). Cell and Gene Therapy (CGT) Access Model Overview Factsheet. https:\/\/www.cms.gov\/files\/document\/cgt-model-ovw-fact-sheet.pdf."},{"key":"10.1016\/j.medj.2026.101151_bib75","unstructured":"Centers for Medicare and Medicaid Services (2025). CMS Expands Access to Lifesaving Gene Therapies Through Innovative State Agreements. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-expands-access-lifesaving-gene-therapies-through-innovative-state-agreements."},{"key":"10.1016\/j.medj.2026.101151_bib76","unstructured":"Centers for Medicare and Medicaid Services (2025). CGT Access Model Frequently Asked Questions. https:\/\/www.cms.gov\/cgt-access-model-frequently-asked-questions."},{"key":"10.1016\/j.medj.2026.101151_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1524-4733.2002.51081.x","article-title":"The economics of gene therapy and of pharmacogenetics","volume":"5","author":"Danzon","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.medj.2026.101151_bib78","first-page":"289","article-title":"Use of health technology assessments in specialty drug coverage decisions by US commercial health plans","volume":"31","author":"Enright","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:49:26Z","timestamp":1789087766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666634026001546"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101151","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy and cost-effectiveness analysis: Current issues and future research","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101151"}}